From: The immunoregulatory mechanisms of carcinoma for its survival and development
Carcinoma type | Distribution of high FasL expression | References |
---|---|---|
Colorectal | 19% in adenomas, 40% of stage I-II, 67% of stage III and 70% of stage IV of carcinoma | [46] |
 | 40.9% in adenoma versus 80.8% in carcinoma | [47] |
 | Higher incidence of metastases and poorer patients' survival associate with FasL positive carcinomas | [48] |
 | 0 positive in normal epithelial cells, 2/7 positive in primary tumors, 4/4 positive in hepatic metastatic tumors | [49] |
Adrenocortical | 37.7% in adenomas versus 100% in the carcinoma | [50] |
Bladder transitional cell | 1) 0% in normal urothelium, 0% in G1, 14% in G2, and 75% in G3. 2) 13% in superficial Ta-T1 versus 81% in invasive T2-T4 | [51] |
 | 0% in normal urothelium, 19% in T1, 21% in T2 and 49% in T3 | [52] |
Pancreatic ductal | 1) 82% in primary versus 100% in hepatic metastases 2) Shorter survival for patients associates with FasL positive tumors | [53] |
Nasopharyngeal | 1) 0% in stage I, 57% in stage II, 58% in stage III and 82% in stage IV; 2) A lower rate of disease-free and overall survival for patients associates with positive FasL expression. | [54] |
Gastric | 36.2% in adenomas, 68.8% in early carcinoma, and 70.4% in advanced carcinoma | [55] |
Cervical | 1) 5/14 in inner 2/3 stromal invasion versus 10/10 outer 2/3 stromal invasion; 2) 7/15 without LN metastasis versus 8/9 with LN metastasis; 3) Reduced survival times in patients with FasL-expressing tumors | [56] |
Esophageal | 1) Higher incidence of LN metastasis associates with the tumors containing >25% FasL expression; 2) All cancer metastases in LN express FasL in >50% of the cells | [57] |